Tool: DupCheckTool: DupCheck

www.DupCheck.org is a web-based tool to screen for duplicate patients in clinical trials within and across studies, sponsors and therapeutic areas. Please visit our "Tools" page for more information.


Project FlyerProject Flyer


Click here to download 
the NEWMEDS project flyer! 


ConsortiumConsortium
consortium teaser

QuicklinksQuicklinks
Project Office Project Office Annual PGB and WP Leads Meetings Annual PGB and WP Leads Meetings Project Governance Project Governance Funding Mechanisms Funding Mechanisms




  Members Area
Username:
Password:



EU
IMI | The Innovative Medicines Initiative
EFPIA | European Federation of Pharmaceutical Industries and Associations

Workpackage 9

Workpackage Objectives

  • Compare the clinical biomarker signatures of schizophrenia with those of preclinical models commonly used in the drug discovery process to aid the development of novel therapies.
  • Integrate the cross species biomarker analysis with other cross species imaging, electrophysiological and cognition efforts (WP 1 -5 ) by studying the same models with these different platforms and identifying the “best” models of the various features of schizophrenia.
  • Use the selected “clinically validated” preclinical models to (a) test the effect of existing and novel antipsychotic drugs on the biomarker fingerprints that overlap with the clinical condition; and (b) identify novel biomarkers and drug targets hypotheses that can support novel drug discovery and development. 

Workpackage Leads

Academic Leads: Prof. Sabine Bahn, The University of Cambridge & Dr. Paul Rodgers, Psynova Neurotech Ltd, UK
EFPIA Lead: Dr. Christian Czech, F. Hoffmann-La Roche AG, Switzerland

Workpackage Partners

  • H. Lundbeck A/S
  • The University of Cambridge
  • Psynova Neurotech Ltd
  • AstraZeneca AB
  • GlaxoSmithKline Research and Development Ltd.
  • Eli Lilly and Company Ltd
  • Janssen Pharmaceutica NV
  • Pfizer Limited
  • Institut de Recherches Servier (observer)

Synergy between academia and industry

There is a major synergy between academia and industry in this workpackage. The overarching goal of WP09 is to provide tools that enable the assessment of a wide selection of potential preclinical models of schizophrenia and, subsequently, depression in terms of the overlap of biomarker profiles with the clinical condition. This is of vital importance to the drug discovery industry as it is clear that current preclinical models of psychiatric disease have been very poor at enabling the development of truly novel therapeutics.
This collaboration between Psynova, the Bahn lab, the academics leading other WPs and EFPIA members enables a close interaction between experts with mutually complementary capabilities and resources. Psynova and the Bahn lab have biomarker discovery, validation and assay development expertise, as well as an existing database of profiling data from clinically defined cohorts (e.g. protein, RNA & metabolomic profiling of prefrontal cortex from schizophrenia patients and carefully matched controls; extensive serum profiling data from multiplexed ELISA assays in drug naive, first onset schizophrenic patients as well as acutely ill depressed patients before and after treatment, etc) relevant to NEWMEDS. EFPIA members bring considerable expertise in using preclinical models for drug discovery. They have worked together to generate a collection of the most interesting preclinical models actively being used by EFPIA members currently and a plan to compare their underlying molecular signatures with those observed in the disease state. This will lead to more insight about which aspects of the disease are best recapitulated in which models and allow for a tailoring of models depending on the goals of the drug developer. The use of similar models from different EFPIA members and from both mice and rats will add to the robustness of the data if it is possible to show similar biomarker signatures from these models. Appealingly, this strategy also provided the tools to allow for interrogation of the wealth of new genetic data appearing in schizophrenia and depression which will spur the development of many new genetically defined preclinical models in the coming years. Once the best models are identified, the biomarker panels also will be used to monitor response to existing and novel drug candidates. In particular, this approach should be very useful in predicting differential efficacy between compounds – a major gap in current models.
Finally, there are also significant synergies with other workpackages in NEWMEDS. Preclinical models prioritised in WP09 will also be studied in other WPs, enabling better translation of clinical endpoints and symptoms (via correlated electrophysiological measures, MRI, metabolism and biomarker changes, etc) between human and preclinical models. Similar combined analysis of the effects on novel drug intervention will aid the development of new therapies targeting the features of the diseases least efficiently addressed by current models (e.g. targeting negative symptoms/cognitive dysfunction in schizophrenia rather than positive symptoms; or looking for more rapid efficacy in antidepressant treatments rather than mechanisms with delayed onset of action).


WP 09 - Proteomic Biomarkers for schizophrenia and depression